Specificity and selectivity evaluations of ligand binding assay of protein therapeutics against concomitant drugs and related endogenous proteins

AAPS Journal

Volumn 9, Issue 2, 2007, Pages E164-E170

  Lee, Jean W ^a   Ma, Hongjin ^a  

^a AMGEN INC   (United States)

Author keywords

Binding assay; Concomitants; Protein therapeutics; Selectivity; Specificity

Indexed keywords

CAPECITABINE; CARBOPLATIN; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; LEUPRORELIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PACLITAXEL; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TRASTUZUMAB; ZOLEDRONIC ACID;

ARTICLE; BINDING ASSAY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; COLON CANCER; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CROSS REACTION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG TARGETING; HEAD AND NECK CANCER; HUMAN; LIGAND BINDING; MONOTHERAPY; PROSTATE CANCER; PROTEIN BINDING; PROTEIN TARGETING; VALIDATION PROCESS;

EID: 34250675994     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/aapsj0902018     Document Type: Article

References (16)

1. Kim S, Prichard CN, Younes MN, et al. Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Clin Cancer Res. 2006;12:600-607.
2. Genovese MC, Cohen S, Moreland L, et al. for the 20000223 Study Group. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum. 2004;50:1412-1419.
3. Ohta M, Konno H, Tanaka T, et al. Effect of combination therapy with matrix metalloproteinase inhibitor MMI-166 and mitomycin C on the growth and liver metastasis of human colon cancer. Cancer Sci. 2001;92:688-695.
4. Antoni C, Kalden JR. Combination therapy of the chimeric monoclonal anti-tumor necrosis factor alpha antibody (infliximab) with methotrexate in patients with rheumatoid arthritis. Clin Exp Rheumatol. 1999;17:S73-S77.
5. de la Gándara J, Rojo JE, Ros S, et al. Neuropharmacological basis of combining antidepressants. Acta Psychiatr Scand. 2005; 112:11-36.
6. Smorenburg CH, Sparreboom A, Bontenbal M, et al. Combination chemotherapy of the taxanes and antimetabolites: its use and limitations. Eur J Cancer. 2001;37:2310-2323.
7. Manni A, Trout D, Verderame MF, et al. Effect of alpha-difluoromethyl-ornithine on the expression and function of the epidermal growth factor receptor in human breast epithelial cells in culture. Breast Cancer Res Treat. 2001;68:139-146.
8. Heeschen C, Dimmeler S, Hamm CW, et al. Prognostic significance of angiogenic growth factor serum levels in patients with acute coronary syndromes. Circulation. 2003;107:524-530.
9. Akil I, Yuksel H, Urk V, et al. Biochemical markers of bone metabolism and calciuria with inhaled budesonide therapy. Pediatr Nephrol. 2004;19:511-515.
10. Vural P, Akgul C, Canbaz M. Effects of hormone replacement therapy on plasma pro-inflammatory and anti-inflammatory cytokines and some bone turnover markers in postmenopausal women. Pharmacol Res. 2006;54:298-302.
11. US Department of Health and Human Services. Guidance for the Industry; Bioanalytical Method Validation. Washington, DC: US Department of Health and Human Services, FDA, CDER, and CVM; 2001.
12. Shah VP, Midha KK, Dighe S, et al. Analytical method validation: bioavailability, bioequivalence, and pharmacokinetic studies. J Pharm Sci. 1992;81:309-312.
13. Shah VP, Midha KK, Findlay JWA, et al. Bioanalytical method validation - a revisit with a decade of progress. Pharm Res. 2000;17:1551-1557.
14. Findlay JWA, Smith WC, Lee JW, et al. Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective. J Pharm Biomed Anal. 2000;21:1249-1273.
15. Miller K, Bowsher RR, Celniker A, et al. Workshop on bioanalytical methods validation for macromolecules: summary report. Pharm Res. 2001;18:1373-1383.
16. DeSilva B, Smith W, Weiner R, et al. Recommendations for the bioanalytical method validation of ligand binding assays to support pharmacokinetic assessments of macromolecules. Pharm Res. 2003;20:1885-1900.